Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

NCT07159906 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma

Interventions

DRUG: Homoharringtonine
DRUG: BCL-2 inhibitor
DRUG: CD20 Antibody
DRUG: Glucocorticoid (GC)

Sponsor

First Affiliated Hospital of Zhejiang University